Overview

The aim of this study is to assess the pharmacokinetics, safety and tolerability of single-dose Adagrasib (BMS-986503) in healthy participants of Japanese descent

Eligibility

Inclusion Criteria:

• Participants must be of Japanese descent (both biological parents of the participant are ethnically Japanese).
• Participants must be healthy adult without clinically significant deviation from normal in medical history, PE, 12-lead ECG, vital sign measurements, and clinical laboratory assessments as determined by the investigator.
• Participants must have Body mass index of 18.0 kg/m2 to 32.0 kg/m2.
• Participants must have Total body weight ≥ 50 kg.

Exclusion Criteria:

• Participants must not have significant history or clinical manifestation of any metabolic, allergic, dermatological, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator.
• Other protocol defined Inclusion/Exclusion criteria apply.